The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Travel, Accommodations, Expenses - Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Grunenthal; Grunenthal; Grunenthal; Grunenthal; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; MSD; MSD; MSD; MSD; Mundipharma; Mundipharma; Mundipharma; Mundipharma; Teva; Teva; Teva; Teva
A phase II study of futibatinib (TAS-120) in patients (pts) with advanced (adv) solid tumors harboring fibroblast growth factor receptor (FGFR) genomic aberrations.
 
Antoine Hollebecque
Honoraria - Merck Serono; Merck Serono; Merck Serono; Merck Serono
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Spectrum Pharmaceuticals (Inst); Spectrum Pharmaceuticals (Inst); Spectrum Pharmaceuticals (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Lilly; Lilly; Lilly; Lilly; SERVIER; SERVIER; SERVIER; SERVIER
Other Relationship - Abbvie; Abbvie; Abbvie; Abbvie; Agios; Agios; Agios; Agios; Amgen; Amgen; Amgen; Amgen; argenx; argenx; argenx; argenx; Arno Therapeutics; Arno Therapeutics; Arno Therapeutics; Arno Therapeutics; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AVEO; AVEO; AVEO; AVEO; Bayer; Bayer; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; FORMA Therapeutics; FORMA Therapeutics; FORMA Therapeutics; FORMA Therapeutics; GamaMabs Pharma; GamaMabs Pharma; GamaMabs Pharma; GamaMabs Pharma; Genentech; Genentech; Genentech; Genentech; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; H3 Biomedicine; H3 Biomedicine; H3 Biomedicine; H3 Biomedicine; Innate Pharma; Innate Pharma; Innate Pharma; Innate Pharma; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Lilly; Lilly; Lilly; Lilly; Loxo; Loxo; Loxo; Loxo; Lytix Biopharma; Lytix Biopharma; Lytix Biopharma; Lytix Biopharma; MedImmune; MedImmune; MedImmune; MedImmune; Menarini; Menarini; Menarini; Menarini; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merrimack; Merrimack; Merrimack; Merrimack; Merus; Merus; Merus; Merus; Millenium Pharamceuticals; Millenium Pharamceuticals; Millenium Pharamceuticals; Millenium Pharamceuticals; Nanobiotix; Nanobiotix; Nanobiotix; Nanobiotix; Nektar; Nektar; Nektar; Nektar; Novartis; Novartis; Novartis; Novartis; Octimet; Octimet; Octimet; Octimet; Oncoethix; Oncoethix; Oncoethix; Oncoethix; Onyx; Onyx; Onyx; Onyx; Orion; Orion; Orion; Orion; Oryzon Genomics; Oryzon Genomics; Oryzon Genomics; Oryzon Genomics; Pfizer; Pfizer; Pfizer; Pfizer; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Roche; Roche; Roche; Roche; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; SERVIER; SERVIER; SERVIER; SERVIER; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Tesaro; Tesaro; Tesaro; Tesaro; Xencor; Xencor; Xencor; Xencor
 
Toshihiko Doi
Honoraria - Abbvie; Abbvie; Abbvie; Abbvie; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Rakuten Medical; Rakuten Medical; Rakuten Medical; Rakuten Medical; Sumitomo Dainippon; Sumitomo Dainippon; Sumitomo Dainippon; Sumitomo Dainippon; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Quintiles (Inst); Quintiles (Inst); Quintiles (Inst); Quintiles (Inst); Sumitomo Group (Inst); Sumitomo Group (Inst); Sumitomo Group (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Omar Saavedra
No Relationships to Disclose
 
Osamu Takahashi
Employment - Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Helen He
Employment - Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Karim A. Benhadji
Employment - Lilly; Lilly; Lilly; Lilly; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly
 
Kohei Shitara
Honoraria - Abbvie; Abbvie; Abbvie; Abbvie; Novartis; Novartis; Novartis; Novartis; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer; Takeda; Takeda; Takeda; Takeda
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)